PTSM: Pharmaceutical Technology Sourcing and Management, Oct 5, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Oct 5, 2011
APIs
A Changing Paradigm for Pharmaceutical Chemical Outsourcing
By Patricia Van Arnum
Industry experts share perspectives on the changing fundamentals and business models for outsourcing pharmaceutical chemical development and manufacturing
Biologics
A Mixed Review for Biotechnology Financing
By Patricia Van Arnum
The biotechnology industry achieved aggregate profitability in 2010 and funding improved, but levels of innovation capital still lag.
Outsourcing
The EU Debt Crisis and CMOs
By Jim Miller
The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
CSR and Sustainability Forum
UN General Assembly Addresses Issue of Noncommunicable Diseases in the Developing World
By Patricia Van Arnum
The United Nations calls for a multistakeholder plan by 2013 to curb the rise of noncommunicable diseases.
Pharmaceutical Industry Prioritizes Its Action Plan for Tackling Noncommunicable Diseases
By Patricia Van Arnum
The International Federation of Pharmaceutical Manufacturers and Associations offers an action plan and research for addressing noncommunicable diseases.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here